Can glomerulosclerosis be reversed?

Nature Clinical Practice Nephrology

Volumn 2, Issue 6, 2006, Pages 290-291

  Fogo, Agnes B ^a,b  

^a Medicine and Pediatrics   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSARTAN; SPIRONOLACTONE; VASCULOTROPIN;

CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; GLOMERULOSCLEROSIS; HUMAN; KIDNEY PARENCHYMA; NEPHRECTOMY; NONHUMAN; OUTCOME ASSESSMENT; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REMISSION; SHORT SURVEY; TREATMENT OUTCOME;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; DISEASE MODELS, ANIMAL; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; KIDNEY FUNCTION TESTS; KIDNEY GLOMERULUS; RATS;

EID: 33745967981     PISSN: 17458323     EISSN: 17458331     Source Type: Journal    
DOI: 10.1038/ncpneph0200     Document Type: Short Survey

References (10)

1. Fogo A (2001) Progression and potential regression of glomerulosclerosis. Kidney Int 59: 804-819
2. Adamczak M et al. (2003) Reversal of glomerulosclerosis after high-dose enalapril treatment in subtotally nephrectomized rats. J Am Soc Nephrol 14: 2833-2842
3. Adamczak M et al. (2004) Reversal of glomerular lesions involves coordinated restructuring of g lomerular microvasculature. J Am Soc Nephrol 15: 3063-3072
4. Zoja C et al. (2002) How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach. J Am Soc Nephrol 13: 2898-2908
5. Fujihara CK et al. (2005) An extremely high dose of losartan affords superior renoprotection in the remnant model. Kidney Int 67: 1913-1924
6. Boffa JJ et al. (2003) Regression of renal vascular and glomerular fibrosis: role of angiotensin II receptor antagonism and matrix metalloproteinases. J Am Soc Nephrol 14: 1132-1144
7. Ma LJ et al. (2005) Regression of glomerulosclerosis with high-dose angiotensin inhibition is linked to decreased plasminogen activator inhibitor-1. J Am Soc Nephrol 16: 966-976
8. Aldigier JC et al. (2005) Regression of existing glomerulosclerosis by inhibition of aldosterone. J Am Soc Nephrol 16: 3306-3314
9. Kang DH et al. (2001) Impaired angiogenesis in the remnant kidney model: II. Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function. J Am Soc Nephrol 12: 1448-1457
10. Liang X et al. Angiotensin type 1 receptor blocker restores podocyte potential to promote glomerular endothelial outgrowth. J Am Soc Nephrol, in press